Screening and follow-up of the patient at high risk for breast cancer

Obstetrics and Gynecology

Volumn 110, Issue 6, 2007, Pages 1404-1416

  Willey, Shawna C ^a,b   Cocilovo, Costanza ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^b WOMEN AND INFANTS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; BRCA1 PROTEIN; BRCA2 PROTEIN; EXEMESTANE; LETROZOLE; PLACEBO; RALOXIFENE; TAMOXIFEN; TAMOXIFEN CITRATE;

ARTHRALGIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RISK; CANCER SCREENING; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DRUG MECHANISM; ENDOMETRIUM CANCER; FOLLOW UP; GENE MUTATION; HIGH RISK PATIENT; HORMONE SUBSTITUTION; HUMAN; MAMMOGRAPHY; MASTECTOMY; MONOTHERAPY; MUTATIONAL ANALYSIS; MYALGIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPOROSIS; PRIORITY JOURNAL; PROPHYLAXIS; RADIATION EXPOSURE; REVIEW; RISK FACTOR; SALPINGOOOPHORECTOMY; SIDE EFFECT; THROMBOEMBOLISM; TUMOR BIOPSY; ADULT; AGED; BREAST TUMOR; FEMALE; GENETIC PREDISPOSITION; GENETICS; MASS SCREENING; MIDDLE AGED; MUTATION; RISK; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MAGNETIC RESONANCE IMAGING; MASS SCREENING; MIDDLE AGED; MUTATION; ODDS RATIO; RISK FACTORS;

EID: 38449088899     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.AOG.0000295638.83285.97     Document Type: Review

References (45)

1. Silva OE, Zurrida S. Breast cancer: a practical guide. 3rd ed. New York (NY): Elsevier; 2005. p. 26-63.
2. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 17 Regs Limited-Use, Nov 2006 Sub (2000-2004). National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2007, based on the November 2006 submission Nov 2006 Sub (2000-2004). Available at: http:/seer.cancer.gov/faststats/sites.php?stat=Incidence&site= Breast+Cancer&x=8&y=20. Retrieved October 31, 2007.
3. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879-86.
4. National Cancer Institute. Breast cancer risk assessment tool. Available at: http://www.cancer.gov/bcrisktool/. Retrieved October 4, 2007.
5. Gail MH, Costantino JP. Validating and improving models for projecting the absolute risk of breast cancer. J Natl Cancer Inst 2001;93:334-5.
6. Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer 1994;73:643-51.
7. Centers for Disease Control and Prevention. Facts about DES & breast cancer. Available at: http://www.cdc.gov/des/partners/download/ DES&BreastCancerFS.pdf. Retrieved October 4, 2007.
8. Pike MC, Spicer DV, Dahmoush L, Press MF. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 1993;15:17-35.
9. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk [published erratum appears in JAMA 2000;284:2597]. JAMA 2000;283:485-91.
10. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985;312:146-51.
11. Dupont WD, Parl FF, Hartmann WH, Brinton LA, Winfield AC, Worrell JA, et al. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer 1993;71:1258-65.
12. Santiago RJ, Wu L, Harris E, Fox K, Schultz D, Glick J, et al. Fifteen-year results of breast-conserving surgery and definitive irradiation for Stage I and II breast carcinoma: the University of Pennsylvania experience. Int J Radiat Oncol Biol Phys 2004;58:233-40.
13. Clemons M, Loijens L, Goss P. Breast cancer risk following irradiation for Hodgkin's disease. Cancer Treat Rev 2000;26:291-302.
14. Land CE, Tokunaga M, Koyama K, Soda M, Preston DL, Nishimori I, et al. Incidence of female breast cancer among atomic bomb survivors, Hiroshima and Nagasaki, 1950-1990. Radiat Res 2003;160:707-17.
15. Smith-Warner SA, Spiegelman D, Yaun SS, van den Brandt PA, Folsom AR, Goldbohm RA, et al. Alcohol and breast cancer in women: a pooled analysis of cohort studies. JAMA 1998;279:535-40.
16. Michels KB, Mohllajee AP, Roset-Bahmanyar E, Beehler GP, Moysich KB. Diet and breast cancer: a review of the prospective observational studies. Cancer 2007;109 suppl:2712-49.
17. Wu AH, Pike MC, Stram DO. Meta-analysis: dietary fat intake, serum estrogen levels, and the risk of breast cancer. J Natl Cancer Inst 1999;91:529-34.
18. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005;97:1652-62.
19. National Comprehensive Cancer Network. NCCN Practice Guidelines in Oncology. Breast Cancer. v. 1.2006. Available at: http://www.nccn.org/ professionals/physician_gls/PDF/breastscreening.pdf Retrieved October 4, 2007.
20. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies [published erratum appears in Am J Hum Genet 2003;73:709]. Am J Hum Genet 2003;72:1117-30.
21. Chlebowski RT. Breast cancer risk reduction: strategies for women at increased risk. Annu Rev Med 2002;53:519-40.
22. Wrensch MR, Petrakis NL, King EB, Miike R, Mason L, Chew KL, et al. Breast cancer incidence in women with abnormal cytology in nipple aspirates of breast fluid. Am J Epidemiol 1992;135:130-41.
23. Fabian CJ, Kimler BF, Mayo MS, Khan SA. Breast-tissue sampling for risk assessment and prevention. Endocr Relat Cancer 2005;12:185-213.
24. van Leeuwen FE, Klokman WJ, Stovall M, Dahler EC, van't Veer MB, Noordijk EM, et al. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 2003;95:971-80.
25. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
26. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12.
27. Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estrogen-only therapy. Obstet Gynecol 2006;108:1354-60.
28. Kendall A, Dowsett M, Folkerd E, Smith I. Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol 2006;17:584-7.
29. Byrne C, Schairer C, Wolfe J, Parekh N, Salane M, Brinton LA, et al. Mammographic features and breast cancer risk: effects with time, age, and menopause status. J Natl Cancer Inst 1995;87:1622-9.
30. Tamimi RM, Byrne C, Colditz GA, Hankinson SE. Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst 2007;99:1178-87.
31. Narod SA, Brunet JS, Ghadirian P, Robson M, Heimdal K, Neuhausen SL, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 2000;356:1876-81.
32. King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 2001;286:2251-6.
33. Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 2001;65:125-34.
34. Defining the role of raloxifene for the prevention of breast cancer. J Natl Cancer Inst 2004;96:1731-3.
35. National Cancer Institute. The study of tamoxifen and raloxifene (STAR): questions and answers. Available at: http://www.cancer. gov/newscenter/ pressreleases/STARresultsQandA. Retrieved October 5, 2007.
36. Kendall A, Dowsett M. Novel concepts for the chemoprevention of breast cancer through aromatase inhibition. Endocr Relat Cancer 2006;13:827-37.
37. Hartmann LC, Schaid DJ, Woods JE, Crotty TP, Myers JL, Arnold PG, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999;340:77-84.
38. Hartmann LC, Sellers TA, Schaid DJ, Frank TS, Soderberg CL, Sitta DL, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 2001;93:1633-7.
39. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002;346:suppl:1616-22.
40. Smith RA, Saslow D, Sawyer KA, Burke W, Costanza ME, Evans WP, et al. American Cancer Society guidelines for breast cancer screening: update 2003. CA: a cancer journal for clinicians 2003 May-Jun;53 (3):141-69.
41. (ACOG) American College of Obstetricians and Gynecologists. ACOG practice bulletin. Clinical management guidelines for obstetrician- gynecologists. Number 42, April 2003. Breast cancer screening. Obstet Gynecol 2003;101:821-31.
42. Bluemke DA, Gatsonis CA, Chen MH, DeAngelis GA, DeBruhl N, Harms S, et al. Magnetic resonance imaging of the breast prior to biopsy. JAMA 2004;292:2735-42.
43. Plevritis SK, Kurian AW, Sigal BM, Daniel BL, Ikeda DM, Stockdale FE, et al. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. JAMA 2006;295:2374-84.
44. Port ER, Park A, Borgen PI, Morris E, Montgomery LL. Results of MRI screening for breast cancer in high-risk patients with LCIS and atypical hyperplasia. Ann Surg Oncol 2007;14:1051-7.
45. Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography [published erratum appears in CA Cancer J Clin 2007;57:185]. CA Cancer J Clin 2007;57:75-89.